Last updated: August 31, 2026
Ulipristal acetate has two distinct commercial histories. The 30 mg product is an emergency contraceptive marketed as ella in the United States and ellaOne in Europe. The 5 mg product, marketed as Esmya and Fibristal for uterine fibroids, lost its European commercial position after serious liver-injury concerns. Current value is concentrated in emergency contraception, where generic entry, low dosing frequency, public-policy changes, and nonprescription access determine demand.
Product-level revenue is not publicly disclosed by Perrigo, the current owner of HRA Pharma’s consumer-health portfolio. The financial trajectory is therefore best assessed through regulatory status, generic competition, channel access, and market structure rather than reported product revenue.
What is ulipristal acetate used for?
Ulipristal acetate is a selective progesterone receptor modulator. Its principal continuing use is emergency contraception after unprotected intercourse or contraceptive failure.
| Product |
Dose |
Indication |
Principal markets |
Current commercial position |
| ella |
30 mg |
Emergency contraception |
United States |
Prescription product; generic competition exists |
| ellaOne |
30 mg |
Emergency contraception |
European Union and other markets |
Generally pharmacy- or nonprescription-access product, subject to national rules |
| Esmya |
5 mg |
Uterine fibroids |
European Union |
EU authorization withdrawn after liver-safety concerns |
| Fibristal |
5 mg |
Uterine fibroids |
Canada |
Commercial status materially impaired by liver-safety restrictions |
Ulipristal 30 mg can be used for emergency contraception up to 120 hours after intercourse. Its commercial differentiation from levonorgestrel emergency contraceptives is strongest later in the five-day window and in patients with higher body weight, although clinical guidance and labeling vary by jurisdiction (U.S. Food and Drug Administration [FDA], 2010; European Medicines Agency [EMA], 2015).
The 5 mg formulation was developed for intermittent treatment of fibroid symptoms. That indication created a substantially larger theoretical treatment market than emergency contraception but also exposed the product to a more demanding chronic-use safety profile.
When did ulipristal acetate lose exclusivity?
Ulipristal acetate’s original small-molecule exclusivity has expired in the principal markets. The remaining commercial protection is primarily brand recognition, distribution, regulatory approvals, trademarks, and market access rather than a durable composition-of-matter patent position.
U.S. exclusivity timeline
| Event |
Date |
Commercial effect |
| FDA approval of ella 30 mg |
Aug. 13, 2010 |
Originator U.S. launch |
| New chemical entity exclusivity |
Approximately 2015 |
Regulatory exclusivity ended |
| Emergency-contraception patent and regulatory protection |
Largely expired or commercially weakened by the early 2020s |
Opened the market to generic entry |
| U.S. generic approvals |
Early 2020s |
Increased price and formulary pressure |
| Current status |
2024 |
Brand and generic ulipristal products compete |
The exact live patent position must be determined from the current FDA Orange Book and applicable court records because listed patents, pediatric exclusivity, and litigation certifications can change. The practical market conclusion is clear: ella no longer has the exclusivity profile of a protected innovative product.
What is the FDA regulatory status of ella and generic ulipristal?
The FDA approved ella under NDA 022474 as a prescription emergency contraceptive in 2010. The approved product contains 30 mg of ulipristal acetate in a single tablet (FDA, 2010).
U.S. regulatory characteristics include:
- Prescription-only status for ella.
- Single-dose administration.
- Use within 120 hours after unprotected intercourse or contraceptive failure.
- No abortion indication.
- No protection against sexually transmitted infections.
- Label warnings concerning repeated use within the same menstrual cycle and interaction with hormonal contraception.
- Potential reduction in efficacy with strong CYP3A4 inducers.
Generic products approved through abbreviated new drug applications can rely on the reference product’s safety and efficacy record, subject to bioequivalence and applicable labeling requirements. Generic ulipristal tablets create direct substitution pressure because the dosage form is simple and the treatment is usually a one-tablet purchase.
In contrast, the 5 mg fibroid products face a different regulatory environment. The EMA concluded that the risk of serious liver injury outweighed the benefits in the remaining patient population and recommended withdrawal of Esmya’s marketing authorization in 2020 (EMA, 2020).
What is the Orange Book status of ulipristal acetate?
The relevant U.S. reference product is ella, NDA 022474. Orange Book analysis should distinguish:
- The original NDA.
- Any patents listed for the 30 mg product.
- Regulatory exclusivity codes.
- Approved generic applicants.
- Patent certifications and any associated litigation.
The commercial significance of the Orange Book position is limited because the principal product is an old small-molecule emergency contraceptive with generic approvals. Any remaining listed patent would need to cover a commercially relevant claim, remain enforceable, and survive invalidity and noninfringement challenges.
A current Orange Book review is necessary before relying on a particular patent number, expiration date, or Paragraph IV status. The FDA Orange Book remains the controlling source for live U.S. listed-patent information (FDA, 2024a).
How many patents cover ulipristal acetate?
The historical estate includes patents directed to steroidal selective progesterone receptor modulators, ulipristal compounds, pharmaceutical compositions, and therapeutic uses. The strongest early protection was directed to the active compound and its medicinal use. Those rights have generally reached the end of their commercial life in the United States and Europe.
The current risk profile is more likely to arise from:
- Formulation or dosage-form claims.
- Manufacturing or polymorph claims.
- Method-of-use claims with narrow patient or timing limitations.
- Jurisdiction-specific secondary patents.
- Trade-secret manufacturing know-how.
A broad, blocking composition-of-matter patent would have materially changed the generic-entry analysis. The present market does not appear to depend on such an unexpired foundational patent in the United States or European Union.
What formulations are protected by ulipristal patents?
The principal commercial formulation is a conventional immediate-release oral tablet. It does not require a complex delivery system, device, depot formulation, or biologic manufacturing process.
That simplicity reduces formulation barriers. A generic applicant can generally compete through:
- The same active ingredient and strength.
- Bioequivalent immediate-release tablets.
- Comparable dissolution and stability.
- Standard oral solid-dose manufacturing.
Formulation patents, if still enforceable in a specific jurisdiction, would need to offer a meaningful barrier against a conventional tablet. The risk is therefore lower than for products protected by extended-release technology, injectables, inhalation devices, or complex biologic formulations.
What patent litigation affects ulipristal acetate?
No major continuing U.S. patent litigation is central to the commercial outlook for ella as of the public regulatory record through 2024. The main competitive event is generic approval and market entry rather than a high-value patent trial.
Potential litigation exposure remains possible if an applicant files a Paragraph IV certification against a listed patent. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. The NDA holder may then file suit, triggering a potential 30-month stay under the Hatch-Waxman framework.
The practical litigation profile is moderate to low because:
- The active ingredient is old.
- The product has a simple formulation.
- The original exclusivity period has ended.
- Generic entry is commercially feasible.
- Emergency contraception is usually purchased as an episodic, low-volume treatment rather than a chronic therapy.
The absence of a major public litigation campaign does not eliminate jurisdiction-specific disputes. It indicates that patent litigation has not become the primary value driver.
Which companies are challenging the ulipristal acetate market?
Generic competition is the principal challenge to HRA Pharma’s ella brand. U.S. generic approvals have been reported for manufacturers including Lupin, with other applicants potentially entering through ANDA pathways or authorized-distribution arrangements.
The competitive field includes:
| Competitor group |
Product type |
Competitive effect |
| HRA Pharma/Perrigo |
ella |
Originator brand and regulatory reference product |
| U.S. generic manufacturers |
Ulipristal acetate 30 mg tablets |
Price erosion and pharmacy substitution |
| Levonorgestrel brands |
Plan B and generics |
Larger and more established emergency-contraception segment |
| Online pharmacies and telehealth providers |
Prescription fulfillment |
Expand access and reduce brand loyalty |
| International manufacturers |
ellaOne or local equivalents |
Increase supply outside the United States |
The largest competitive threat is not another ulipristal product. It is the lower-cost levonorgestrel category, which has broader consumer familiarity and, in the United States, greater retail availability.
How does ulipristal acetate compare with levonorgestrel emergency contraception?
Ulipristal has a clinically differentiated position, but its commercial position is weaker than its clinical differentiation suggests.
| Factor |
Ulipristal acetate |
Levonorgestrel |
| Common dose |
30 mg once |
1.5 mg once |
| Treatment window |
Up to 120 hours |
Best within 72 hours; reduced efficacy later |
| U.S. prescription status |
ella remains prescription-only |
Many levonorgestrel products are available over the counter |
| Generic availability |
Yes |
Extensive |
| Consumer familiarity |
Lower |
Higher |
| Price pressure |
Increasing |
High |
| Main clinical advantage |
Later-window use and potentially better performance at higher body weight |
Convenience and immediate retail access |
The prescription requirement for ella creates friction, especially when consumers need rapid access. Telehealth and online pharmacy channels partially reduce that disadvantage. Over-the-counter conversion would improve access but could also accelerate generic substitution and reduce the originator’s brand premium.
What is the financial trajectory for ulipristal acetate?
The financial trajectory has four phases.
1. Innovation and launch phase
The 2010 U.S. approval created a differentiated emergency-contraception product with a five-day use window. Initial value came from regulatory exclusivity, clinical differentiation, and brand positioning.
2. Expansion and international commercialization
The 30 mg product gained broader international distribution as ellaOne and related brands. The European market generally provided more direct pharmacy access than the U.S. prescription model.
The 5 mg fibroid indication created an additional revenue opportunity, but that opportunity depended on intermittent or repeated treatment and carried substantially greater safety-monitoring requirements.
3. Fibroid-indication contraction
Liver-injury reports led to restrictions on Esmya, including monitoring and limitations on patient eligibility. The EMA later recommended withdrawal of the authorization. This removed a major component of potential ulipristal revenue in Europe and impaired the value of the 5 mg franchise (EMA, 2020).
4. Generic and portfolio-management phase
The continuing 30 mg emergency-contraception business is a mature branded-generic market. Revenue is likely driven by:
- Prescription volume.
- Emergency-contraception demand.
- Reproductive-health policy.
- Pharmacy and telehealth access.
- Generic price competition.
- International OTC or pharmacy status.
- Supply continuity.
Perrigo acquired HRA Pharma in 2022 for approximately $1.9 billion, expanding its consumer-health portfolio, which included ella and ellaOne-related assets (Perrigo Company plc, 2022). Perrigo does not report ella revenue as a separately material public segment. That limits precise valuation of ulipristal sales and requires portfolio-level analysis.
What is the revenue exposure to ulipristal acetate?
Revenue exposure is concentrated but not strategically dominant for Perrigo.
Key observations are:
- The product is a single-dose therapy, so annual treatment frequency is tied to incidence of need rather than chronic adherence.
- Gross revenue is exposed to generic substitution and retailer bargaining power.
- Emergency-contraception demand can increase during changes in abortion access, contraceptive policy, or public awareness.
- Demand can also shift to levonorgestrel products or copper intrauterine devices.
- The discontinued or restricted fibroid business no longer provides the same growth platform.
- Perrigo’s diversified consumer-health portfolio reduces corporate dependence on ella.
For investors, ulipristal should be modeled as a mature, policy-sensitive consumer-health asset with limited exclusivity upside. A forecast based on sustained brand pricing would be vulnerable to generic entry, prescription-access constraints, and channel substitution.
What generic launch risks exist for ulipristal acetate?
Generic launch risk is material because the product has low technical complexity.
Base-case scenario
Generic manufacturers gain pharmacy and payer access. ella retains a brand segment among prescribers, telehealth providers, and consumers who request the original product. Net price declines, while total category volume remains stable or increases modestly.
Upside scenario for the originator
The originator preserves a premium through distribution, consumer recognition, supply reliability, and stronger telehealth integration. Regulatory or commercial barriers delay generic substitution.
Downside scenario
Multiple generics enter, pharmacies substitute automatically, and the prescription-only status limits the originator’s ability to differentiate. Net sales decline faster than category demand.
The product does not present the manufacturing barriers seen in sterile injectables or biologics. Active-ingredient sourcing, tablet manufacturing, analytical testing, and regulatory compliance are the main requirements.
What is the biosimilar risk for ulipristal acetate?
There is no biosimilar risk because ulipristal acetate is a chemically synthesized small molecule. The relevant threat is conventional generic competition under the ANDA pathway.
This distinction matters commercially. Biosimilar entry often involves interchangeability, physician adoption, manufacturing scale, and complex regulatory evidence. Ulipristal competition is more direct and can occur through standard pharmaceutical-equivalence and bioequivalence pathways.
How strong is the ulipristal acetate patent estate?
The estate is weak as a current broad-market exclusivity platform and stronger as a historical innovation estate.
| Patent-estate factor |
Assessment |
| Foundational active-ingredient protection |
Largely expired in major markets |
| Regulatory exclusivity |
Expired |
| Formulation complexity |
Low |
| Manufacturing barriers |
Moderate for API quality and consistency, low for finished tablets |
| Method-of-use protection |
Potentially narrow and jurisdiction-specific |
| Biosimilar barrier |
Not applicable |
| Generic substitution risk |
High |
| Remaining commercial moat |
Brand, distribution, access, and supply |
The most valuable surviving rights, if any, would likely be narrow secondary claims rather than a broad blockade of ulipristal acetate tablets.
What geographic markets matter most for ulipristal acetate?
The United States and European markets have different value drivers.
United States
The U.S. market is shaped by:
- Prescription-only access for ella.
- Generic ANDA competition.
- Telehealth and online pharmacy distribution.
- Competition from over-the-counter levonorgestrel.
- Political and legal changes affecting reproductive-health demand.
European Union
The EU market historically provided broader pharmacy access for ellaOne. Demand is influenced by national reimbursement policies, pharmacy protocols, and local nonprescription rules.
The 5 mg Esmya franchise suffered a major loss of geographic coverage after the EMA liver-safety action. That event reduced the European value of ulipristal beyond emergency contraception.
Other markets
Local product approvals, emergency-contraception guidelines, prescription rules, and patent enforcement determine value. The same product may be OTC in one country, prescription-only in another, and unavailable in a third.
What licensing deals affect ulipristal acetate?
The most commercially important transaction was Perrigo’s acquisition of HRA Pharma in 2022. The transaction transferred control of HRA Pharma’s consumer-health portfolio, including ella, to Perrigo (Perrigo Company plc, 2022).
Earlier commercialization involved HRA Pharma and regional partners for ellaOne and related products. Licensing economics vary by territory and are not generally disclosed at the product level. No publicly reported licensing arrangement changes the basic patent conclusion: current value is driven by commercial execution rather than a newly created exclusivity estate.
Key Takeaways
- Ulipristal acetate remains commercially relevant primarily as 30 mg emergency contraception.
- ella is FDA-approved but remains prescription-only in the United States.
- Generic ulipristal competition has materially weakened the originator’s pricing power.
- The 5 mg fibroid franchise lost substantial value after liver-safety restrictions and European withdrawal of Esmya.
- There is no biosimilar risk; conventional generic competition is the relevant threat.
- The original patent and regulatory-exclusivity platform has largely expired.
- The principal remaining moat is brand, distribution, access, supply reliability, and international channel positioning.
- Perrigo does not separately report ella revenue, limiting product-level financial modeling.
- Levonorgestrel is the primary commercial competitor because of lower price, broader OTC access, and higher consumer familiarity.
- The asset should be valued as a mature, policy-sensitive consumer-health product rather than as a late-life protected pharmaceutical.
FAQs About Ulipristal Acetate Market and Patent Risk
Is ulipristal acetate still commercially viable?
Yes, but mainly as a mature emergency-contraception product. Commercial viability depends on volume, distribution, access, and cost control rather than patent-protected pricing.
Can ulipristal acetate be purchased without a prescription?
In the United States, ella is prescription-only. ellaOne and equivalent products may be available directly from pharmacies in many European countries, subject to national rules.
Did ulipristal acetate lose its uterine-fibroid market?
It lost much of that market in Europe after liver-safety concerns led to restrictions and withdrawal of Esmya’s authorization. Emergency contraception remains the principal commercial use.
Is ulipristal acetate protected by a formulation patent?
The commercial product is a conventional immediate-release tablet. Any surviving formulation rights would likely be narrower than the original active-ingredient protection and would need current jurisdiction-specific verification.
What would most increase ulipristal acetate sales?
Wider nonprescription access, stronger telehealth distribution, increased demand for five-day emergency contraception, and reduced generic substitution would have the greatest potential impact. Policy changes can increase category demand but may also benefit lower-priced competitors.
References
- European Medicines Agency. (2015). ellaOne: EPAR - Product information. https://www.ema.europa.eu
- European Medicines Agency. (2020). EMA recommends withdrawal of marketing authorisation for ulipristal acetate for uterine fibroids. https://www.ema.europa.eu
- Perrigo Company plc. (2022). Perrigo completes acquisition of HRA Pharma. https://investor.perrigo.com
- U.S. Food and Drug Administration. (2010). FDA approves ella emergency contraceptive. https://www.fda.gov
- U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database, NDA 022474. https://www.accessdata.fda.gov/scripts/cder/daf/
